CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

被引：13
|
作者：
Le, Xiuning
Garassino, Marina Chiara
Cornelissen, Robin
Socinski, Mark A.
Tchekmedyian, Nishan
Molina, Julian R.
Baik, Christina S.
Leu, Sharon
Dreiling, Lyndah
Lebel, Francois M.
Clarke, Jeffrey Melson
机构：
[1] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] IRCCS, Natl Canc Inst, Dept Med Oncol, Milan, Italy
[3] Erasmus MC, Rotterdam, Netherlands
[4] Advent Hlth Hematol & Oncol, Orlando, FL USA
[5] Pacif Shores Med Grp, Huntington Beach, CA USA
[6] Mayo Clin, Rochester, MN USA
[7] Seattle Canc Care Alliance, Seattle, WA USA
[8] Spectrum Pharmaceut, Irvine, CA USA
[9] Duke Univ, Med Ctr, Durham, NC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 15期
关键词：
D O I：
10.1200/JCO.2021.39.15_suppl.9093
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9093
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.
    Ou, Sai-Hong Ignatius
    Lin, Huamao Mark
    Hong, Jin-Liern
    Yin, Yu
    Jin, Shu
    Lin, Jianchang
    Mehta, Minal
    Nguyen, Danny
    Neal, Joel W.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [2] Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib
    不详
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [3] Poziotinib in NSCLC harbouring EGFR or HER2 exon 20 insertion mutation
    Prelaj, A.
    Bottiglieri, A.
    Galli, E.
    Lo Russo, G.
    Ferrara, R.
    Galli, G.
    De Toma, A.
    Brambilla, M.
    Occhipinti, M.
    Manglaviti, S.
    Beninato, T.
    Zattarin, E.
    Apollonio, G.
    Ganzinelli, M.
    Gallucci, R.
    Di Mauro, R. M.
    de Braud, F.
    Torri, V.
    Garassino, M. C. C.
    Proto, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S976 - S977
  • [4] Preclinical Modeling of Osimertinib for NSCLC With EGFR Exon 20 Insertion Mutations
    Lee, Yusoo
    Kim, Tae Min
    Kim, Dong-Wan
    Kim, Soyeon
    Kim, Miso
    Keam, Bhumsuk
    Ku, Ja-Lok
    Heo, Dae Seog
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : 1556 - 1566
  • [5] Sunvozertinib in NSCLC Patients with EGFR Exon20 Insertion Mutations
    Bazhenova, L.
    Yang, J. Chih-Hsin
    Wang, M.
    Mitchell, P.
    Camidge, D. Ross
    Fang, J.
    Nian, W.
    Chiu, C. -H.
    Zhou, J.
    Zhao, Y.
    Su, W. -C.
    Yang, T. -Y.
    Zhu, V. W.
    Millward, M.
    Fan, Y.
    Huang, W. -T.
    Cheng, Y.
    Jiang, L.
    Zheng, L.
    Janne, P. A.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (03) : E3 - E3
  • [6] The Preclinical and Clinical Activity of Poziotinib, a Potent, Selective Inhibitor of EGFR Exon 20 Mutant NSCLC
    Elamin, Y.
    Robichaux, J.
    Lam, V.
    Tsao, A.
    Lu, C.
    Blumenschein, G.
    Kurie, J.
    Brahmer, J.
    Li, S.
    Chen, T.
    Estrada-Bernal, A.
    Truini, A.
    Nilsson, M.
    Le, A.
    Tan, Z.
    Zhang, S.
    Doebele, R.
    Politi, K.
    Yang, Z.
    Liu, S.
    Wong, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S1776 - S1776
  • [7] Successful Treatment of a Miliary Metastatic NSCLC Patient With Activating EGFR Exon 20 Insertion Mutation with Response to Poziotinib
    Yang, Juyin
    Yang, Jian
    Ban, Shao
    Li, Xinmin
    Chen, Xingde
    Yang, Jihua
    Qian, Jun
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (09) : E198 - E200
  • [8] ZENITH20, a multinational, multi-cohort phase II study of poziotinib in NSCLC patients with EGFR or HER2 exon 20 insertion mutations
    Socinski, M. A.
    Cornelissen, R.
    Garassino, M. C.
    Clarke, J.
    Tchekmedyian, N.
    Molina, J.
    Goldman, J. W.
    Bhat, G.
    Lebel, F.
    Le, X.
    ANNALS OF ONCOLOGY, 2020, 31 : S1188 - S1188
  • [9] Preliminary safety and activity of CLN-081 in NSCLC with EGFR exon 20 insertion mutations (Ins20)
    Piotrowska, Z.
    Nguyen, D.
    Koczywas, M.
    Tchekmedyian, N.
    Clancy, M. S.
    Witter, D.
    Page, A.
    Zawel, L.
    Yu, H. A.
    ANNALS OF ONCOLOGY, 2020, 31 : S862 - S863
  • [10] Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations
    Le, Xiuning
    Nilsson, Monique
    Chatterjee, Sampurna
    Su, Zhenqiang
    He, Junqin
    Udagawa, Hibiki
    Yu, Xiaoxing
    Poteete, Alissa
    Huang, Qian
    Heymach, John V.
    Vincent, Sylvie
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
12345